Patients with melanoma and BRAF mutation are needed for a study

IRB/UVA Tracking #
20968
Principal Investigator
Elizabeth M Gaughan
Contact
Rupert Egan
Contact Phone
434.982.1901
Official Trial Title
A Randomized Phase III trial of Dabrafenib + Trametinib
followed by Ipilimumab + Nivolumab at Progression vs.
Ipilimumab + Nivolumab followed by Dabrafenib +
Trametinib at Progression in Patients With Advanced
BRAFV600 Mutant Melanoma
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for adults ages 18 and over with advanced or metastatic melanoma whose tumor contains a BRAF driver mutation. The purpose of this research study is to compare the effects of receiving immunotherapy followed by BRAF inhibitor therapy if the tumor exhibits progression versus the converse sequence. You will randomly be assigned to one of the two treatment sequences.

Study participation will go on for as long as the melanoma is being controlled. The follow-up period will last for up to 5 years. The treatment regimens and any procedures being done above and beyond standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT02224781

Compensation

N/A